<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1879">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05136703</url>
  </required_header>
  <id_info>
    <org_study_id>20210773</org_study_id>
    <secondary_id>R01MH128868</secondary_id>
    <nct_id>NCT05136703</nct_id>
  </id_info>
  <brief_title>Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)</brief_title>
  <acronym>TRIDENT</acronym>
  <official_title>Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this randomized controlled trial is to understand how a cognitive-behavioral&#xD;
      treatment (a form of psychological treatment) for depression changes the gut microbiome&#xD;
      (micro-organisms that regulate the health of the gut), immune system, and the brain&#xD;
      functioning in people living with HIV.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in resting state activation of the negative valence system</measure>
    <time_frame>6 Months</time_frame>
    <description>Measured by functional Magnetic Resonance Imaging (fMRI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in connectivity of the negative valence system</measure>
    <time_frame>6 Months</time_frame>
    <description>Measured by functional Magnetic Resonance Imaging (fMRI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depressive Symptoms</measure>
    <time_frame>6 Months</time_frame>
    <description>The Hamilton Rating Scale for Depression is an interviewer-administered measure that has a total score ranging from 0-52 with the higher score indicating greater depressive symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gastrointestinal Dysbiosis</measure>
    <time_frame>4 months</time_frame>
    <description>Measured via 16s sequencing of the gut microbiome using rectal swabs and fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conserved transcriptional response to adversity (CTRA) leukocyte signaling pathway</measure>
    <time_frame>4 Months</time_frame>
    <description>Measured using Ribonucleic Acid (RNA) sequencing from peripheral blood mononuclear cells</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Markers of Microbial Translocation</measure>
    <time_frame>4 Months</time_frame>
    <description>Enzyme-linked immunosorbent assay (ELISA) methods will be employed to measure lipopolysaccharide binding protein (LBP) levels in plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Markers of Immune Activation and Inflammation</measure>
    <time_frame>4 Months</time_frame>
    <description>Enzyme-linked immunosorbent assay (ELISA) methods will be employed to measure levels of monocyte activation markers (i.e., soluble CD14, soluble CD163) and pro-inflammatory cytokines (e.g., interluekin-6, high sensitivity c-reactive protein) in plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Markers of Dysregulated Neurotransmitter Synthesis</measure>
    <time_frame>4 Months</time_frame>
    <description>High performance liquid chromatography method with fluorescence will measure mean levels of the kynurenine/tryptophan and phenylalanine/tyrosine ratios in plasma samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive Functioning</measure>
    <time_frame>6 Months</time_frame>
    <description>Changes in mean levels of measures indexing executive functioning, attention, and affect regulation assessed in a comprehensive, interviewer-administered neuropsychological assessment battery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Depression</condition>
  <condition>HIV-1-infection</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive CBT-AD immediately will complete up to 12 individual sessions focused on depression and one session of ART Adherence counseling during the four months following randomization.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Wait-List Control (WLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to the WLC condition will receive one session of ART adherence counseling immediately following randomization. After six months, WLC participants will have the opportunity to receive 12 individually delivered CBT-AD sessions focused on depression.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)</intervention_name>
    <description>CBT-AD is a behavioral intervention administered either in person or via Zoom. Each session lasts approximately 50 minutes. Participants will receive up to 12 individually delivered sessions over 4 months.</description>
    <arm_group_label>Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)</arm_group_label>
    <arm_group_label>Wait-List Control (WLC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Antiretroviral Therapy (ART) Adherence Counseling</intervention_name>
    <description>One ART Adherence counseling session will be administered at the initiation of study participation</description>
    <arm_group_label>Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD)</arm_group_label>
    <arm_group_label>Wait-List Control (WLC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 or older&#xD;
&#xD;
          2. Speaks and reads English&#xD;
&#xD;
          3. Verified HIV+ status with antiretroviral medications bearing his/her name&#xD;
&#xD;
          4. Current diagnosis on Major Depressive Disorder (MDD) using a structured clinical&#xD;
             interview&#xD;
&#xD;
          5. If prescribed antidepressants, on a stable regimen and dose for at least 2 months&#xD;
&#xD;
          6. Clinically elevated C-Reactive Protein (CRP) of &gt; 3 mg/L&#xD;
&#xD;
          7. Undetectable HIV viral load from peripheral venous blood sample&#xD;
&#xD;
          8. Able to complete Functional Magnetic Resonance Imaging (fMRI) scans (i.e., no&#xD;
             claustrophobia, no metal implants, no pacemaker, and BMI &lt; 40)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to provide informed consent&#xD;
&#xD;
          2. Active, untreated major mental illness&#xD;
&#xD;
          3. Pregnancy at baseline&#xD;
&#xD;
          4. Received CBT for depression in the past 2 years&#xD;
&#xD;
          5. Otherwise eligible but does not complete baseline biospecimen collection and fMRI&#xD;
             visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam W Carrico, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam W Carrico, PhD</last_name>
    <phone>305-243-6947</phone>
    <email>a.carrico@miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Adam W Carrico, PhD</last_name>
      <phone>305-243-6947</phone>
      <email>a.carrico@miami.edu</email>
    </contact>
    <investigator>
      <last_name>Adam W Carrico, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Adam Carrico</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Retroviral Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

